IC
GPCR icon

Ikarian Capital’s Structure Therapeutics GPCR Stock Holding History

Ikarian Capital’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-290
Closed -$1.14M – 160
2024
Q2 		$1.14M Sell
290
-120,110
-100% -$4.93M 0.2% 72
2024
Q1 		$5.16M Buy
+120,400
New +$5.08M 0.57% 55

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Ikarian Capital's GPCR Position: Q1 2026 in Review

Ikarian Capital sold out of Structure Therapeutics (GPCR) in Q1 2026, closing a stake of 4,824 shares — an estimated $336K sold.

Ikarian Capital first reported a position in GPCR in Q3 2023 and held it in 8 quarters. The position peaked at $7.7M in Q4 2024. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • Ikarian Capital reported no remaining Structure Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Ikarian Capital sold 4,824 Structure Therapeutics shares in Q1 2026, an estimated $336K.
  • Ikarian Capital first reported a position in Structure Therapeutics in Q3 2023 and held it in 8 quarters.
  • Ikarian Capital's Structure Therapeutics position peaked at $7.7M in Q4 2024.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.